Live feed08:00:00·14mPRReleasevia QuantisnowLantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETsByQuantisnow·Wall Street's wire, on your screen.LNTH· Lantheus Holdings Inc.Health Care
